177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial-Reference-Cited by-同舟云学术

177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial

Published:2021-07-29 Issue: Volume: Page:jnumed.121.262552
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Pathmanandavel Sarennya,Crumbaker Megan,Yam Andrew O.,Nguyen Andrew,Rofe Christopher,Hovey Elizabeth,Gedye Craig,Kwan Edmond M.,Hauser Christine,Azad Arun A.,Eu Peter,Martin Andrew J.,Joshua Anthony M.,Emmett Louise

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival;Cancers;2024-07-26

3. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

4. Combination Strategies and Targeted Radionuclide Therapies;Seminars in Nuclear Medicine;2024-07

5. Anti-Cancer Effects of Soy Isoflavones against Cancer by Radiosensitizing Properties: A Systematic Review;Current Cancer Therapy Reviews;2024-06-21